LISATA THERAPEUTICS, INC. (LSTA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does LISATA THERAPEUTICS, INC. Do?
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. LISATA THERAPEUTICS, INC. (LSTA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David J. Mazzo and employs approximately 30 people, headquartered in BASKING RIDGE, New Jersey. With a market capitalization of $45M, LSTA is one of the notable companies in the Healthcare sector.
LISATA THERAPEUTICS, INC. (LSTA) Stock Rating — Hold (April 2026)
As of April 2026, LISATA THERAPEUTICS, INC. receives a Hold rating with a composite score of 37.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.LSTA ranks #1,145 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LISATA THERAPEUTICS, INC. ranks #85 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
LSTA Stock Price and 52-Week Range
LISATA THERAPEUTICS, INC. (LSTA) currently trades at $5.01. The stock gained $0.01 (0.2%) in the most recent trading session. The 52-week high for LSTA is $5.07, which means the stock is currently trading -1.2% from its annual peak. The 52-week low is $1.81, putting the stock 176.8% above its annual trough. Recent trading volume was 14K shares, suggesting relatively thin trading activity.
Is LSTA Overvalued or Undervalued? — Valuation Analysis
LISATA THERAPEUTICS, INC. (LSTA) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.09x, versus the sector average of 2.75x. The price-to-sales ratio is 645.16x, compared to 1.66x for the average Healthcare stock.
At current multiples, LISATA THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
LISATA THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score
LISATA THERAPEUTICS, INC. (LSTA) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -127.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -104.6% versus the sector average of -33.1%.
The operating margin is -6954.3% (sector: -66.1%). Net profit margin stands at -6655.7%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
LSTA Debt, Balance Sheet, and Financial Health
LISATA THERAPEUTICS, INC. has a debt-to-equity ratio of 22.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.76x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $19M.
LSTA has a beta of 0.80, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for LISATA THERAPEUTICS, INC. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
LISATA THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, LISATA THERAPEUTICS, INC. reported revenue of $70,000 and earnings per share (EPS) of $-1.91. Net income for the quarter was $-19M. Operating income came in at $-20M.
In FY 2025, LISATA THERAPEUTICS, INC. reported revenue of $170,000 and earnings per share (EPS) of $-1.91. Net income for the quarter was $-17M. Revenue grew -83.0% year-over-year compared to FY 2024. Operating income came in at $-18M.
In Q3 2025, LISATA THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.49. Net income for the quarter was $-4M. Operating income came in at $-4M.
In Q2 2025, LISATA THERAPEUTICS, INC. reported revenue of $70,000 and earnings per share (EPS) of $-0.54. Net income for the quarter was $-5M. Operating income came in at $-5M.
Over the past 8 quarters, LISATA THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $0 to $70,000. Investors analyzing LSTA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
LSTA Dividend Yield and Income Analysis
LISATA THERAPEUTICS, INC. (LSTA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
LSTA Momentum and Technical Analysis Profile
LISATA THERAPEUTICS, INC. (LSTA) has a momentum factor score of 73/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.
LSTA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, LISATA THERAPEUTICS, INC. (LSTA) ranks #85 out of 838 stocks based on the Blank Capital composite score. This places LSTA in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing LSTA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LSTA vs S&P 500 (SPY) comparison to assess how LISATA THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.
LSTA Next Earnings Date
No upcoming earnings date has been announced for LISATA THERAPEUTICS, INC. (LSTA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy LSTA? — Investment Thesis Summary
LISATA THERAPEUTICS, INC. presents a balanced picture with arguments on both sides. The quality score of 21/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Price momentum is positive at 73/100, suggesting the trend favors buyers. High volatility (stability score 33/100) increases portfolio risk.
In summary, LISATA THERAPEUTICS, INC. (LSTA) earns a Hold rating with a composite score of 37.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LSTA stock.
Related Resources for LSTA Investors
Explore more research and tools: LSTA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LSTA head-to-head with peers: LSTA vs AZN, LSTA vs SLGL, LSTA vs VMD.